ARS Pharmaceuticals, Inc. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- ARS Pharmaceuticals, Inc. stock issued during period, value, stock options exercised for the quarter ending 2025-09-30 was $479.00K.
- ARS Pharmaceuticals, Inc. stock issued during period, value, stock options exercised for the quarter ending 2023-09-30 was $922.00K.
- ARS Pharmaceuticals, Inc. stock issued during period, value, stock options exercised for the quarter ending 2023-06-30 was $2.74M, a 854.36% increase year-over-year.
- ARS Pharmaceuticals, Inc. stock issued during period, value, stock options exercised for the quarter ending 2023-03-31 was $1.32M, a 6842.11% increase year-over-year.
- ARS Pharmaceuticals, Inc. stock issued during period, value, stock options exercised for fiscal 2021 was $169.00K, a 207.27% increase from fiscal 2020.
- ARS Pharmaceuticals, Inc. stock issued during period, value, stock options exercised for fiscal 2020 was $55.00K.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2025-09-30 | $479.00K 10-Q · filed 2025-11-10 | |
| 2023-09-30 | $922.00K 10-Q · filed 2024-11-13 | |
| 2023-06-30 | $2.74M 10-Q · filed 2023-11-09 | |
| 2023-03-31 | $1.32M 10-Q · filed 2023-11-09 | |
| 2022-06-30 | $287.00K 10-Q · filed 2023-11-09 | |
| 2022-03-31 | $19.00K 10-Q · filed 2022-11-02 | |
| 2021-12-31 | $169.00K 10-K · filed 2023-03-23 | |
| 2021-09-30 | $154.00K 10-Q · filed 2022-11-02 | |
| 2021-03-31 | $254.00K 10-Q · filed 2022-11-02 | |
| 2020-12-31 | $55.00K 10-K · filed 2022-03-31 | |
| 2020-09-30 | $16.00K 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $2.00K 10-Q · filed 2021-11-10 | |
| 2020-03-31 | $6.00K 10-Q · filed 2021-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 |